Rationale Bipolar disorder (BD) is a disabling and lifethreatening disease characterized by states of depression and mania. New and efficacious treatments have not been forthcoming partly due to a lack of well-validated models representing both facets of BD. Objectives We hypothesized that cholinergic-and dopaminergic-pharmacological manipulations would model depression and mania respectively, each attenuated by lithium treatment. Methods C57BL/6 J mice received the acetylcholinesterase inhibitor physostigmine or saline before testing for "behavioral despair" (immobility) in the tail suspension test (TST) and forced swim test (FST). Physostigmine effects on exploration and sensorimotor gating were assessed using the cross-species behavioral pattern monitor (BPM) and prepulse inhibition (PPI) paradigms. Other C57BL/6 J mice received chronic lithium drinking water (300, 600, or 1200 mg/l) before assessing their effects alone in the BPM or with physostigmine on FST performance. Another group was tested with acute GBR12909 (dopamine transporter inhibitor) and chronic lithium (1000 mg/l) in the BPM.
Introduction
Bipolar disorder (BD) is a severely disabling mental illness affecting 1-2 % of the global population for BD type I (Merikangas et al. 2011) . The seriousness of the disorder is indicated by an increased suicide mortality rate (Osby et al. 2001) where one in three patients attempt suicides (Novick et al. 2010 ) and lifetime costs of persons with BD amounting to $24 billion US (Begley et al. 2001) .
BD is a unique mood disorder defined by periods of depression and mania during which symptoms of patients differ markedly (Belmaker and Bersudsky 2004) . In fact, symptoms can be largely opposite from each other with hyperactivity being a hallmark feature of mania (DSM-V 2013) , whereas lethargy or psychomotor retardation characterize depression. Lithium is commonly used to treat aspects of mania and depression as well as maintain a patient's state between periods (Malhi et al. 2012 ), but its effects are limited and it has a low acceptability profile (Cipriani et al. 2011) . Greater understanding of the mechanisms underlying and/or overlapping different phases of BD may improve the development of novel and more efficacious therapeutics.
An improved understanding of mechanisms contributing to each aspect of BD may also lead to better animal models with which to test therapeutics targeted at these mechanisms. The current paucity of treatments may be due in part to the dearth of valid animal models targeting the etiologies of BD (Malkesman et al. 2009; Young et al. 2011a ). Indeed, animal models being used to reproduce a BD-like phenotype are usually specific only to the manic phase of the disorder (Gould et al. 2001; Roybal et al. 2007; van Enkhuizen et al. 2013a ). These models typically reproduce aspects of hyperactivity (Shaldubina et al. 2002) , with some measuring impaired risk-taking (Young et al. 2011b) , and increased reward seeking (van Enkhuizen et al. 2013c ). An awareness exists for the necessity to model the full spectrum of BD (depression and mania) in animals in order to find novel treatments for the full disorder (Machado-Vieira et al. 2004 ), but the complexity of the matter has prevented such an outcome as yet (Young and Dulcis 2015) .
Key difficulties in recreating the range of BD from depression to mania are the evidence of differing mechanisms underlying each aspect of the disorder. Recently, a human imaging study implicated elevated acetylcholine (ACh) levels across all brain regions in both acutely depressed and recovered subjects (Saricicek et al. 2012) . Importantly, the same has also been suggested in BD patients during periods of depression (Hannestad et al. 2013 ). Early observations in animals support depression-relevant behavior in a selectively bred line of rats with increased sensitivity to acetylcholinesterase (AChE; the primary enzyme hydrolyzing ACh), the Flinders Sensitive Line (Overstreet 1993) . More recently, the AChE inhibitor physostigmine induced depression-like behavior in mice (Mineur et al. 2013 ) consistent with physostigmineinduced severe depression and psychomotor retardation in marijuana-intoxicated humans (El-Yousef et al. 1973) as well as increased symptoms of depression in patients with mania, depression, schizoaffective disorder (Janowsky et al. 1974) , and healthy subjects (Risch et al. 1981) . This physostigmineinduced immobility of mice in the forced swim test (FST) was reversed by antidepressant treatment (Mineur et al. 2013) , although the same dose reduced mobility which could have confounded the selectivity of effect. These data provide putative support that increasing ACh levels models the behavior and etiology of depression that is relevant to BD, renewing interest in the cholinergic hypothesis of depression (Janowsky et al. 1974; van Enkhuizen et al. 2015) .
The biological underpinnings of BD mania likely involve mechanisms other than those of depression, however, putatively catecholaminergic in nature (Janowsky et al. 1972; van Enkhuizen et al. 2015) . Previously, we demonstrated that mice with reduced dopamine transporter (DAT) functioning model exploratory profiles of BD mania (Perry et al. 2009 ). Both DAT knockdown (KD) mice and mice receiving the selective DAT inhibitor GBR12909 exhibit hyperactivity, increased exploration, and straight paths of movement as quantified by the mouse behavioral pattern monitor (BPM) (Young et al. 2010a; b) similar to patients with BD mania (Minassian et al. 2011; Perry et al. 2010 ) and euthymia (Henry et al. 2013 ) in a human BPM. Although some of the abnormal behavior observed in these GBR12909-treated mice, such as impaired decision-making (van Enkhuizen et al. 2013b) , is also present in depressed patients with BD performing similar human tasks (Adida et al. 2011) , their hyperactivity, increased motivation , and reduced immobility times in the tail suspension test (TST) (Sarkisyan et al. 2010) and FST (Esumi et al. 2013 ) more closely model the manic phase of BD. Furthermore, dysfunctional sensorimotor gating of the startle reflex as measured by reduced prepulse inhibition (PPI) has been observed in manic patients with BD (Perry et al. 2001 ), but not in depressed subjects (Perry et al. 2004; Quednow et al. 2006) , suggesting that dysfunctional PPI is state dependent (Kohl et al. 2013) . These PPI deficits can be recreated in rodents (Geyer et al. 2002) and have been observed in rodent models of BD mania (van Enkhuizen et al. 2013c) , including mice challenged with GBR12909 (Kwek and van den Buuse 2013) .
These animal data may have etiological relevance to BD because reduced striatal DAT levels are observed in unmedicated patients with BD (Anand et al. 2011) as well as in postmortem tissue (Rao et al. 2012) . Thus, hyperdopaminergia caused by reduced DAT levels has been used to model mania-like behavior in mice.
To date, the effect of the same treatments approved for depression and mania have yet to be determined on behaviors induced by physostigmine or reductions in DAT function. Chronic lithium treatment can treat both mania and depression. We hypothesized that (1) physostigmine would induce depression-like effects measured by "behavioral despair" in mice by using the TST (Cryan et al. 2005) and FST (Petit-Demouliere et al. 2005) and that (2) lithium would attenuate these effects in the FST. To address mania-relevant behaviors, we used human and rodent cross-species tests of exploration in the BPM and PPI in the acoustic startle test , predicting that (3) physostigmine would not recreate mania-relevant behaviors while (4) GBR12909 treatment would recreate mania-relevant behaviors, an effect attenuated by lithium treatment.
Methods Animals
Male (n=136) and female (n=51) C57BL/6 J mice were used in these studies (Fig. 1 ). Mice were maintained in a temperature-controlled vivarium (21±1°C) on a reversed day/ night cycle (lights on at 7:00 p.m., off at 7:00 a.m.) and were tested during the dark phase between 8:00 am. and 5:00 p.m. Mice were group housed (four/cage), weighed between 20 and 40 g, and were 3-4 months old at the time of testing. Mice had ad libitum access to water and food (Harlan, Madison, WI, USA) except during testing with lithium (see below). All procedures were approved by the UCSD Institutional Animal Care and Use Committee. The UCSD animal facility meets all federal and state requirements for animal care and was approved by the American Association for Accreditation of Laboratory Animal Care.
Drug treatment
GBR12909 dihydrochloride and physostigmine sulfate (Sigma-Aldrich, St Louis, MO, USA) were both dissolved in 0.9 % saline vehicle (10 ml/kg), GBR12909 after sonicating for 2-4 h at 40°C (van Enkhuizen et al. 2013a; Young et al. 2010b ). GBR12909 (13 mg/kg) was administered by i.p. injection immediately prior to the experiment (Loos et al. 2010; van Enkhuizen et al. 2013a; van Enkhuizen et al. 2013b ) and physostigmine (0.01, 0.03, 0.1, and 0.3 mg/kg) by i.p. injection 30 min prior to the experiment as done previously (Clark et al. 2005; Dunstan and Jackson 1977; Gard et al. 2012) . Initially, lithium chloride (Sigma-Aldrich, St Louis, MO, USA) was dissolved into the drinking water at 300, 600, or 1200 mg/l and given for 10-17 days (Fig. 1) . This procedure was chosen based on previous studies using procedures with 600 and 1200 mg/l to achieve serum levels approaching human therapeutic concentrations (Fig. 2) (Dehpour et al. 1995; Roybal et al. 2007 ). After we acquired serum levels with these doses, we tested 1000 mg/l lithium dissolved into the drinking water for the BPM and GBR12909 experiment hypothesizing this dose would produce therapeutic serum levels. Control animals received tap water. Drug doses were calculated as the weight of the free-base, except for lithium chloride.
Serum lithium measurements
Mice were decapitated and trunk blood was collected. Blood was left to clot for approximately 15 min and then centrifuged Fig. 1 Timeline of the testing procedures for the current studies. One group of male mice (n=40; a) were tested in the TST, BPM, PPI, and FST, respectively. Over the four tests, each animal received each drug dose or saline once. Drug or saline was administered 30 min prior to testing in the TST and FST, and 10 and 55 min prior to the BPM and PPI test, respectively. Another group of male mice (n=96; b) was treated with either lithium in their drinking water (300, 600, or 1200 mg/l) or normal tap water (vehicle) after baseline-matching. After 10 days of treatment, half of each group was tested in the BPM. One week later and 17 days of lithium treatment, half of each group received saline or physostigmine in counter-balanced order 30 min prior to testing in the FST. Other naïve mice (n=51; c) received vehicle or 1000 mg/l lithium solution for 7 days. Half of each group was administered saline or GBR12909 immediately prior to testing in the BPM. Doses are in milligrams/kilograms unless indicated otherwise Fig. 2 Serum concentrations of lithium after 17 days of different doses of lithium treatment in drinking water. Lithium (Li) at 300 mg/l resulted in low serum levels (0.17±0.04 mmol/l), while 1200 mg/l resulted in high/toxic Li concentrations (1.34±0.25 mmol/l). Drinking water with Li 600 mg/l resulted in low therapeutic serum concentrations for bipolar disorder (0.46±0.14 mmol/l). Comparative lithium levels are provided from earlier publications, the variability from which is discussed below. Data are presented as mean±S.E.M. for 10 min. Serum was removed and frozen. Samples were analyzed by using spectrophotometry performed by the UCSD Medical Center (USA).
Mouse behavioral pattern monitor
Locomotor behavior and exploration were examined in eight mouse BPM chambers (San Diego Instruments, USA) as described previously (Risbrough et al. 2006; Tanaka et al. 2012) . In brief, each Plexiglas arena consists of a 30.5×61×38 cm area with three floor and eight wall holes (three in each long wall and one in each short wall; 1.25 cm in diameter, 1.9 cm from the floor), each equipped with an infrared photobeam to detect holepoking. Each chamber is enclosed in an outer box with an internal white house light above the arena (350 lx in the center and 92 lx in the four corners) that minimizes external light and noise. Activity was obtained from a grid of 12×24 infrared photobeams 1 cm above the floor (2.5 cm apart; 24×12 X-Y array), recording the location of the mouse every 0.1 s, with its position defined across nine unequal regions (four corners, four walls, and center (Geyer et al. 1986) ). Another set of 16 photobeams, placed 2.5 cm above the floor, was used to detect rearing behavior. At the start of the session, mice were placed in the bottom left-hand corner of the arena and the test session started immediately. The primary outcome measures were transitions across the defined regions and center entries (locomotor activity), holepoking and rearing (exploratory behavior), and spatial d (dimensionality of locomotor patterns). Spatial d measures the degree to which the animal makes more straight-line movements versus more circumscribed paths of movement. It quantifies the geometric dimensionality of the locomotor path, where a value closer to 1 reflects a one-dimensional straight path, and values closer to 2 indicating highly circumscribed smallscale movements (Paulus and Geyer 1991) .
Acoustic startle testing
Startle and PPI testing were examined in eight startle chambers (SR-LAB, San Diego Instruments, USA), using an experimental session as described previously (van Enkhuizen et al. 2013c) . Each chamber consists of a Plexiglas cylinder, 5 cm in diameter, resting on a platform in a ventilated soundattenuating outer box. Speakers mounted 33 cm above the cylinders produced all acoustic stimuli, and movements of the animal were transduced by piezoelectric accelerometers mounted under the cylinders and stored and digitized by an interface and computer assembly. Mice were placed into the startle chambers and testing started after a 5-min acclimation period. Mice were exposed to a 65-dB background sound and light, located on the ceiling of the chamber, continuously throughout the session. Startle pulses were 40 ms and prepulses were 20 ms in duration. The inter-trial interval (ISI) between stimulus presentations ranged between 3 and 12 s (7 s average). The acoustic startle sessions included five blocks. The first block consisted of five 120-dB pulses. The second block included prepulse trials (69, 73, and 81 dB) preceding a 120-dB pulse. The third block included acoustic startle responding only (80, 90, 100, 110, and 120 dB pulses). The fourth block varied the ISI, consisting of 73 dB prepulses preceding 120 dB pulses by 25, 50, 100, 200, and 500 ms. The fifth and final block delivered five 120-dB pulses and together with 120-dB pulses in each block served to assess habituation. PPI was calculated as a percentage score for each prepulse intensity based on the 120-dB pulse within that block: %PPI=100−[(startle magnitude for prepulse+pulse/startle magnitude for pulse alone)×100].
Tail suspension test
Assessing immobility in the TST is commonly used to screen for compounds with antidepressant efficacy and is also used to identify depression-like behavior in mice (Cryan et al. 2005) . Mice were gently suspended by the tip of the tail attached with a piece of adhesive tape to a metal bar placed horizontally 50 cm above the tabletop. Videotapes were scored by an experimenter blind to the experimental treatment for time spent immobile over 6 min. The primary outcome measure was immobility defined as no movement except for respiration.
Forced swim (Porsolt) test
Consistent with the TST, the FST was devised to screen for compounds with antidepressant efficacy and is based on observing so-called "behavioral despair." Mice were placed in a clear glass beaker with a diameter of 15 cm, a height of 24 cm, and 15 cm of tap water at 25°C. The duration of the test was 6 min, and videotapes were scored for all 6 min by a trained investigator blind to the experimental treatment. The primary outcome measure was immobility defined as no movement except minor movement required to keep afloat. After the test, the animal was dried and returned to its home cage. The water was replaced between every 5-6 animals in order to retain correct temperature and cleanliness.
Experiments
For a more detailed description of the animals used, and the experimental timeline, see Fig. 1 . Figure 2 provides information on the serum levels produced by 300, 600, or 1200 mg/l of lithium as well as compared with other studies.
Exp 1a: assessing the effects of physostigmine on immobility in the TST Mice received saline or 0.03, 0.1, or 0.3 mg/kg physostigmine 30 min prior to testing (n=10/group).
Exp 1b: assessing the effects of physostigmine on immobility in the FST After observing a strong lethargy-inducing effect with 0.3 mg/kg physostigmine treatment in the BPM, we investigated a lower dose of this compound in the FST. Mice received saline or 0.01, 0.03, or 0.1 mg/kg physostigmine 30 min prior to testing (n=10/group).
Exp 1c: assessing the effects of lithium on physostigmine-induced increased immobility in the FST Mice (n=96) received chronic lithium (300, 600, or 1200 mg/ l) or regular drinking water (vehicle) for 17 days. Because mice treated with lithium 1200 mg/l had experienced severe side-effects (including some deaths), only mice treated with lithium 300 or 600 mg/l were tested. These mice then received saline or 0.03 mg/kg physostigmine 30 min prior to testing (n=12/group).
Exp 2a: assessing the effects of physostigmine on exploration in the BPM
Mice were tested in the BPM for 45 min and received saline or 0.03, 0.1, or 0.3 mg/kg physostigmine 10 min prior to testing (n=10/group).
Exp 2b: assessing the effects of physostigmine on PPI in the acoustic startle test
Immediately after experiment 2a, mice were tested in the acoustic startle test. Hence, these mice had received saline or 0.03, 0.1, or 0.3 mg/kg physostigmine 55 min prior to testing (n=10/group).
Exp 3a: assessing the effects of lithium on exploration in the BPM Mice (n=48) were tested first without drug in the BPM for 30 min to match their baseline behavior based on transitions, holepoking, rearing, and spatial d. They were then counterbalanced into groups that received regular tap water (vehicle; n=12) or lithium solution (n=12/dose). After 10 days of treatment, mice were tested in the BPM for 60 min.
Exp 3b: assessing the effects of lithium on GBR12909-induced hyper-exploration in the BPM Treatment-naive female C57BL/6 mice received tap water (vehicle; n=24) or 1000 mg/l lithium solution (n=27). After 7 days of treatment, half of these groups received saline or GBR12909 (13 mg/kg; n≈12/group) immediately prior to assessing their exploration in the BPM for 60 min.
Statistical analyses
We first confirmed that all data was distributed normally and displayed equal variances. Data from the BPM and acoustic startle test were analyzed using two-or three-way analyses of variance (ANOVA), with GBR12909 and lithium treatment as between-subject factors and time-period (15 min), prepulse intensity, pulse intensity, ISI, or habituation block as withinsubject factors. TST and FST data were analyzed using a oneor two-way ANOVA with drug and dose of lithium treatment as between-subject factors. Tukey post hoc analyses of main or interaction effects were performed where applicable. The animals' body weights were compared using an independent samples t test. All BPM and startle data were analyzed using the BMDP statistical software (Statistical Solutions Inc., USA), while TST and FST data were analyzed using SPSS (19.0, Chicago, IL, USA). The α level was set to 0.05.
Results
Experiment 1a: the effects of physostigmine on immobility in the TST Three saline-treated mice were excluded from analyses, due to climbing their tail. Physostigmine significantly increased immobility time (F(3,33)=16.3, p<0.001; Fig. 3a) , at each dose compared to saline (p<0.001).
Experiment 1b: the effects of physostigmine on immobility in the FST Consistent with the TST, physostigmine increased immobility time in the FST (F(3,36)=8.0, p<0.001; Fig. 3b ), at 0.03 and 0.1 mg/kg (p<0.001), but not 0.01 mg/kg (p>0.05), compared to saline.
Experiment 1c: the effects of lithium on physostigmine-induced increased immobility in the FST
A few mice were excluded from analyses because of unforeseen death (due to circumstances not related to lithium treatment). When analyzed including both lithium doses, there was a main effect of lithium (F(2,60)=10.4, p<0.001) and physostigmine (F(1,60)=4.2, p<0.05), but no interaction between both (F(2,60)=2.3, p>0.05). Given the numerical distinction that the main effect was at 600 mg/l, the data were re-analyzed comparing lithium 600 mg/l to saline treatment. A main effect of lithium (F(1,42) = 15.4, p < 0.001) and lithium by physostigmine interaction (F(1,42)=4.2, p<0.05; Fig. 3c) were observed, without a main effect of physostigmine (F(1, 42)=4.2, p>0.05). Hence, despite the evidence that lithium exerted overall antidepressant-like effects, the focused analysis revealed that this effect was driven by 600 mg/l lithium treatment in physostigmine-treated mice. Post hoc analyses confirmed that physostigmine increased immobility time compared to saline in the vehicle-(p<0.01), but not the lithiumtreated animals (p >0.05). Hence, treatment with lithium 600 mg/l attenuated the physostigmine-induced increased immobility (p<0.001). Lithium did not affect mice receiving saline (p>0.05). We also observed the mice for potential adverse effects of lithium. No adverse effects on health were reported; neither were differences in weight observed between vehicle-treated mice (28.0 g) and mice treated with lithium 300 mg/l (27.3 g; t(46)=1.0, p>0.05) or lithium 600 mg/l (26.0 g; t(45)=1.5, p>0.05).
Experiment 2a: the effects of physostigmine on exploration in the BPM

Locomotor behavior
Mice receiving physostigmine exhibited significantly reduced transitions (F(3,36)=55.0, p<0.001; Fig. 4a ) and center entries (F(3,36)=26.1, p<0.001; Fig. 4b ),
Exploratory behavior
Physostigmine significantly reduced holepoking (F(3,36)= 44.9, p < 0.001; Fig. 4c ) and rearing (F(3,36) = 33.5, p<0.001; Fig. 4d ) in mice.
Locomotor patterns
Physostigmine significantly increased spatial d in mice (F(3, 36)=34.1, p<0.001; Fig. 4e ). Only 0.3 mg/kg physostigmine increased spatial d compared to saline (p<0.001), although the low activity limits the exact measurement of spatial d.
Post hoc analyses confirmed that only the two highest doses of physostigmine (0.1 and 0.3 mg/kg) reduced transitions, center entries, holepokes, and rearing (p<0.001). The lowest dose (0.03 mg/kg) did not affect any of the above measures compared with vehicle (p>0.05). When split by three 15-min time bins, there were significant time by physostigmine interactions for transitions (F(6,72)=12.2, p<0.001), center entries (F(6,72)=2.3, p<0.05), holepoking (F(6,72)= 7.4, p<0.001), and rearing (F(6,72)=5.5, p<0.001), reflecting that mice treated with 0.1 mg/kg physostigmine approached control levels of behavior over time (Fig. 4f ).
Experiment 2b: the effects of physostigmine on PPI in the acoustic startle test
A main effect of prepulse (F(2,72)=129.0, p<0.001; Fig. 5a ) revealed that PPI improved with higher prepulse intensities, providing construct validity. A main effect of physostigmine (F(3, 36)=8.7, p<0.001) and interaction with prepulse (F(6,72)=3.3, p<0.01) were observed. Post hoc analyses revealed that 0.3 mg/kg physostigmine increased PPI at each prepulse intensity (p<0.01), while 0.03 mg/kg tended to increase PPI only at a 69-dB prepulse intensity (p<0.1). There was also a trend effect of physostigmine on startle amplitude (F(3,36)=2.6, p<0.1; Fig. 5b ) and a pulse by physostigmine interaction (F(12,144)= 1.8, p<0.05). No post hoc effects were observed however. When Fig. 3 Time spent immobile in the TST and FST after physostigmine administration and its reversal by lithium in the FST. Each dose of physostigmine increased immobility times compared to saline in the TST (a). Both 0.03 and 0.1 mg/kg increased immobility times compared to saline in the FST, but 0.01 mg/kg had no effect (b). In another group of mice, physostigmine (Phy; 0.03 mg/kg) increased immobility times compared to saline (Sal) in the vehicle-treated mice (Veh), but after a more focused re-analysis, this physostigmine-induced immobility was not observed in the mice treated with lithium 600 mg/l (c). Data are presented as mean+S.E.M. n=10-12 animals per group. **p<0.01 and *** p<0.001 when compared to saline and^^^p<0.001 when compared to vehicle split by ISI, there was a main effect of physostigmine (F(3,36)= 3.6, p<0.05; Fig. 5c ). Post hoc analyses revealed that consistent with its effects on PPI at varying prepulse intensity levels, 0.3 mg/kg physostigmine increased PPI at ISI 100 (p<0.01) and tended to at ISI 500 (p<0.1). All mice habituated over time (F(4,144)=15.5, p<0.001; Fig. 5d ), without effect of physostigmine treatment (F(3,36)=1.6, p>0.05). No effect of physostigmine was observed on movement when no stimuli were presented (F(3,36)=1.9, p>0.05; Fig. 5e ). Finally, in mice matched for startle reactivity (n=14), there was still a main effect of physostigmine on PPI (F(3,30)=6.0, p<0.01) with 0.3 mg/kg increasing PPI at each prepulse intensity (p<0.05).
Experiment 3a: the effects of different doses lithium on exploration in the BPM
Locomotor behavior
There were no main effects of lithium on transitions, nor on center entries (F<1, p>0.05; Fig. 6a-b) . Post hoc analyses revealed no differences between doses of lithium and vehicle treatment.
Exploratory behavior
There were no effects of lithium on holepoking or rearing (F< 1, p>0.05; Fig. 6c-d) .
Locomotor patterns
There was a main effect of lithium on spatial d (F(3, 44)=3.3, p<0.05; Fig. 6e ). Post hoc analyses revealed no differences between lithium and vehicle treatment however.
We also examined the potential adverse effect of lithium on the animals' body weights and observed no difference between vehicle-treated mice (27.5 g) and mice treated with lithium 300 mg/l (26.8 g; t(22)<1, p>0.05) or lithium 600 mg/l (25.4 g; t(21)=1.1, p>0.05). Mice treated with lithium 1200 mg/l had significantly lower body weights compared to vehicle however (23.9 g; t(22)=3.2, p<0.005).
Experiment 3b: the effects of lithium 1000 mg/l on GBR12909-induced hyper-exploration in the BPM
Locomotor behavior
A main effect of GBR12909 was observed for transitions (F(1,47)=7.0, p<0.05; Fig. 7a ), but not center entries (Fig. 7b ). There were no main effects of or interactions with lithium treatment for transitions or center entries. Post hoc analyses revealed that GBR12909 increased transitions in the vehicle-treated (p<0.05), but not in the lithiumtreated mice. Fig. 7c ) and rearing (F(1,47)=11.5, p<0.01; Fig. 7d ).
There were no main effects of or interactions with lithium treatment for holepoking or rearing. Post hoc analyses revealed that GBR12909 increased holepoking and rearing in the vehicletreated (p<0.05), but not in the lithium-treated mice. Fig. 5 Effects of physostigmine on sensorimotor gating of the acoustic startle response of mice. The highest dose of physostigmine (0.3 mg/kg) increased PPI compared to saline (Sal) whereas 0.03 mg/kg only tended to increase PPI at the lowest prepulse (a). Physostigmine had no effect on overall amplitude of the startle response (b). When split by ISI, 0.3 mg/kg physostigmine increased PPI at ISI 100 (c). All mice exhibited habituation over time, without effect of physostigmine treatment (d) . No difference between drug and saline was observed when no stimulus was presented (e). Data are presented as mean+S.E.M. n=10 animals per group. **p<0.01 when compared to saline Fig. 6 The effects of chronic lithium on the exploratory profile of mice in the BPM. There were no significant effects of lithium on transitions (a) or center entries (b). No differences between any dose of lithium and vehicle treatment were observed for holepoking (c) or rearing (d). Although there was a main effect of lithium on spatial d, no differences between doses of lithium and vehicle treatment were observed (e). Data are presented as mean+S.E.M. n=12 animals per group
Locomotor patterns
There was a main effect of GBR12909 for spatial d (F(1,47)= 26.5, p<0.001; Fig. 7e ), but no lithium effect or interaction between both. Post hoc analyses revealed that GBR12909 reduced spatial d in both vehicle-treated mice and lithiumtreated mice (p<0.05).
When body weight was examined, it was observed that mice treated with lithium 1000 mg/l (23.8 g) had significantly lower body weights compared to vehicle-treated mice (25.4 g) (t(49)=2.2, p<0.05).
Discussion
We examined the potential use of cholinergic and dopaminergic manipulations to model BD facets of depression and mania in mice, respectively. The AChE inhibitor physostigmine induced depression-like behavior in mice similar to human observations and consistent with the increased ACh levels observed in the pathophysiology of depressed patients. Importantly for BD research, this increased ACh-induced "behavioral despair" was normalized by the mood-stabilizer lithium. Reducing DAT functioning via GBR12909 treatment Fig. 7 Chronic lithium-induced attenuation of DAT blockadeinduced mania-like exploratory behavior in the BPM. GBR12909 significantly increased activity as measured by transitions in both groups although only in vehiclebut not chronic lithium-treated mice in post hoc tests (a). There were no effects on center entries (b). GBR12909 induced hyperexploration as measured by increased holepoking (c) and rearing (d) overall, but not in lithium-treated mice after post hoc assessment. Treatment with GBR12909 resulted in more linear patterns of movement as deduced from lower spatial d overall in both vehicle-and lithium-treated mice (e). Data are presented as mean+S.E.M. n≈12 animals per group. **p<0.05 and ***p<0.01 when compared to saline induced a mania-like state in mice as measured by hyper-exploration. Similar to its reversal of physostigmine-induced depression-like behavior, chronic lithium attenuated GBR12909-induced hyper-exploration, although it did not alter the effect of GBR12909 on behavioral organization. Thus, by targeting diverse etiologically relevant mechanisms, separate models of both depression and mania can be generated pharmacologically that are both partially responsive to lithium treatment.
Physostigmine administration induced depression-like behavior in mice, replicating its depression-inducing effects in humans (Risch et al. 1981) . This depression-like behavior was interpreted from physostigmine increasing immobility times in the TST and FST at doses that were not sedative, an effect consistent with previous reports of physostigmine-induced immobility in mice (Mineur et al. 2013 ) and rats (Hasey and Hanin 1991) that may be hippocampally mediated (Mineur et al. 2013 ). Mineur et al. reported that 0.5 mg/kg physostigmine induced depression-like behavior without affecting motor activity. In contrast, we observed that 0.03 mg/kg increased immobility without affecting locomotion, while 0.3 mg/kg severely depressed locomotion and immobility. The sources of the differences between these dosing reports remain unclear, although reduced locomotor activity has been observed before with physostigmine at doses above 0.1 mg/kg (Dunstan and Jackson 1977) , but not as low as 0.03 mg/kg. Here, 0.03 mg/kg physostigmine increased immobility in the TST and FST, without affecting activity in the BPM, supporting the conclusion that physostigmine induced "behavioral despair"/depression-like behavior rather than an overall suppression of activity. Higher physostigmine doses decreased activity and exploration (0.1 and 0.3 mg/kg), and produced severely localized movements (0.3 mg/kg). To determine the cross-species relevance of these findings, current studies are investigating the human exploratory profile of patients with both unipolar and bipolar depression in the BPM.
At high doses, physostigmine increased PPI in the acoustic startle test, consistent with previous results at similar doses (Clark et al. 2005 ). This effect is unlikely due to sedation since increases in PPI were also seen in mice matched for startle reactivity. In support of a non-sedating effect explaining physostigmine-induced increases in PPI, locomotor activity had normalized by the time its effects on PPI were tested (Fig. 4f) . The immobility-inducing dose of 0.03 mg/kg did not affect PPI. Although PPI has yet to be studied in depressed bipolar patients, PPI is unaffected in unipolar depression (Perry et al. 2004; Quednow et al. 2006) , supporting the disease-relevance of these findings. Future studies will investigate sensorimotor gating across the spectrum of BD, but it is likely that active manic symptoms and/or acute psychosis are necessary to exhibit PPI deficits (Kohl et al. 2013) .
Previously, we observed a consistent pattern of increased activity, increased exploration, and more linear patterns of movement in mice administered GBR12909 or DAT KD mice in the mouse BPM (Perry et al. 2009; Young et al. 2010a; b) , mimicking the behavior of manic (Minassian et al. 2011 ) and euthymic BD patients (Henry et al. 2013 ). In the current studies, GBR12909 at 13 mg/kg again produced this mania-like behavior in mice. Recently, we reported that chronic valproate at human therapeutic blood levels for BD attenuated the mania-like pattern induced by GBR12909 (van Enkhuizen et al. 2013a) . Moreover, GBR12909 increased measures of motivation (van Enkhuizen et al. 2013b ) and sped responding in mice , while low doses (5 mg/kg) also reduced immobility time in the FST (Esumi et al. 2013) and impaired PPI (Kwek and van den Buuse 2013) , consistent with reported PPI deficits in patients with BD mania (Perry et al. 2001) . Increasing DA functional activity by inhibiting the DAT thus results in different facets of behavior in rodents relevant to mania in humans.
Previously, we showed that valproate only attenuated GBR12909-induced hyperactivity compared with vehicletreated mice, without affecting their specific exploration (van Enkhuizen et al. 2013a ). Earlier studies with lithium in chow (1.2 and 2.4 %) were terminated due to concerns for the health of the mice (e.g., polydipsia and severe weight loss, despite making saline available; unpublished observations). Lithium 600 mg/l administered chronically in drinking water resulted in low therapeutic blood concentrations consistent with previous studies of 10-21 days lithium administration (Fig. 2 ) (Dehpour et al. 2002; Ghasemi et al. 2009; Roybal et al. 2007 ). Lithium at 300 mg/l resulted in serum concentrations below therapeutic levels and was not effective in reversing immobility. No adverse health or weight effects were observed with 300 or 600 mg/l. Lithium at 1000 mg/l, however, resulted in a slight weight loss (1.5 g). Lithium treatment at 1200 mg/l resulted in toxic blood concentrations, and a more severe loss of weight (3.6 g). Other studies examining 1200 mg/l of lithium resulted in lower concentrations likely because measurements were taken from the brain tissue (Beaulieu et al. 2008) and after only 10 days of treatment (Dehpour et al. 1995) . Future behavioral studies with chronic lithium should include pretreatment weights in their design and include a bottle of saline for mice in order to better regulate the potential lithiuminduced electrolyte imbalance. Based on our serum concentration studies, a dose of 1000 mg/l would likely yield serum concentrations in the therapeutic range for BD to block switching to a manic state. Lithium at 1000 mg/l indeed attenuated the effects of GBR12909 on exploration and activity, although significant differences compared to GBR12909+ve-hicle pretreatment were not observed, in contrast to results with valproate (van Enkhuizen et al. 2013a ). Lithium did not attenuate GBR12909-induced effects on behavioral organization of these mice as measured by spatial d. In contrast, lithium counteracted amphetamine-induced hyperactivity (Gould et al. 2007 ), an effect that may have been mediated by reductions in catecholamine synthesis and release (Berggren 1985) . In terms of depression-like behavior, chronic lithium treatment at 600 mg/l reduced overall immobility as indicated by a main effect, consistent with previous findings (Bersudsky et al. 2007; Can et al. 2011) . Specifically, however, lithium normalized the physostigmine-induced immobility without affecting vehicle-treated mice. Physostigmine-induced immobility was similarly reversed by acute treatment with the antidepressant fluoxetine (Mineur et al. 2013) , although immobility was also reduced in control mice. The "antidepressant" effect of lithium observed here may be due to compensation of physostigmine-induced reduction of AChE levels, since lithium can increase AChE levels (Varela et al. 2013) . Lithium also increases cholinergic functioning (Jope 1979) and augments seizure-and catalepsy-inducing effects of pilocarpine in rats however (Jope and Morrisett 1986; Lerer 1985) . Clearly, a comprehensive explanation of the mechanism of action of lithium is unclear, but likely entails parallel effects on the catecholamine and acetylcholine neurotransmitter systems. Ultimately, lithium prevents mania relapses in only approximately 50 % of patients (Geddes et al. 2004) , hence further investigation and better treatments are required. Future studies examining other behaviors relevant to bipolar depression and mania are required.
The present studies support the premise of a cholinergic/ catecholaminergic mechanism that differentiates states of BD (van Enkhuizen et al. 2015) . Research investigating how the same subjects may cycle between these different neurobiological states during depression and mania is required. Altered light exposure has been theorized to contribute to these extreme behaviors (Sherman 2012 ) and indeed changing light exposure can switch neurotransmitter levels in rats (Dulcis et al. 2013) . Utilizing this environmental manipulation alongside animals with a genetic susceptibility to BD (Malkesman et al. 2009 ) may provide a model animal with which to test novel therapeutics to treat the entire spectrum of BD (Young and Dulcis 2015) . Thus, instead of reproducing depression-and mania-like behaviors using two separate manipulations, these combined challenges may mimic BD more accurately in a single model animal.
For future testing, improving the techniques used to measure depression-like behavior would prove useful. Although increased immobility times are commonly used to identify depression-like behavior, there is a debate as to whether the FST and TST can only be used to screen for antidepressantlike activity and may not reflect depressive states per se. Future studies could assess more complex behaviors related to cognition given its importance to functional outcome for patients with BD (Green 2006) . For example, examining dynamic decision-making in models of BD mania and depression could be useful. Patients across the spectrum exhibit poor decision-making (Adida et al. 2011) , but this effect may be driven by a hypersensitivity to rewards during the manic phase (Brambilla et al. 2012; van Enkhuizen et al. 2014a ), yet a hypersensitivity to punishments during the depressed phase (Adida et al. 2011) . Future tests should also assess other treatments available such as antipsychotics and antidepressants in these models of BD depression-and mania-like behavior. Finally, although most studies reported here used males, females were used to develop evidence of lithium-induced blockade of GBR12909-induced mania-relevant profiles, demonstrating treatment efficacy across sexes. Considering BD affects both males and females, these studies require testing in both sexes in future studies.
In conclusion, we described separate animal models of both depressive-and mania-like facets of BD by manipulating the cholinergic and dopaminergic pathways, respectively, and assessing the efficacy of chronic treatment with lithium. These models support the hypotheses that the neurobiological underpinnings may vary dependent upon the phases of BD (van Enkhuizen et al. 2014b) . Understanding the mechanism(s) under which the neurobiology of patients change will be vital for blocking the cycling that occurs in patients (Young and Dulcis 2015) . Meanwhile, the currently described models provide a way of testing novel therapeutics targeted at symptoms exhibited during different stages of BD.
